CMBA
AVNR

C.M. Bidwell & Associates’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

C.M. Bidwell & Associates’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-27,585
Closed -$329K – 281
2014
Q3 		$329K Buy
+27,585
New +$188K 0.08% 109

Other funds holding AVNR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

C.M. Bidwell & Associates's AVNR Position: Q4 2014 in Review

C.M. Bidwell & Associates sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q4 2014, closing a stake of 27,585 shares — an estimated $329K sold.

C.M. Bidwell & Associates first reported a position in AVNR in Q3 2014 and held it in 1 quarter. The position peaked at $329K in Q3 2014. 166 funds tracked by Wall St. Rank hold AVNR as of Q4 2014.

  • C.M. Bidwell & Associates reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q4 2014 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 27,585 AVANIR PHARMACEUTICALS, INC CL A shares in Q4 2014, an estimated $329K.
  • C.M. Bidwell & Associates first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q3 2014 and held it in 1 quarter.
  • C.M. Bidwell & Associates's AVANIR PHARMACEUTICALS, INC CL A position peaked at $329K in Q3 2014.
  • 166 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q4 2014.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2014, filed 9 Feb 2015.